Antiplatelet drug market to face big transition

Published: 2011-01-21 06:58:00

Updated: 2011-01-21 06:58:00

The domestic antiplatelet drugs market will undergo a major transformation as AstraZenca is set to launch its new platelet aggregation inhibitor Brilinta (ticagrelor) in the latter half of this year.

So far, Sanofi-Aventis’s Plavix (clopidogrel) kept its number 1 ranking in terms of revenue, b...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK